Pharma Journalist -

Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta (Aβ) oligomers (AβOs) for the treatment of…
Read More...

Bayer announced the inauguration of its new life science incubator, Bayer Co.Lab Shanghai, in the Shanghai Innovation (SH-INNO) Park at the heart of China´s largest biopharma cluster,…
Read More...

Boehringer Ingelheim has entered a partnership with the NCD Alliance, a network dedicated to shaping a world in which everyone can live a healthy and productive life, free from the…
Read More...

Phare Bio, along with the Collins Lab at the Massachusetts Institute of Technology (MIT) and Harvard's Wyss Institute, announced that they have been awarded up to $27 million in funding…
Read More...

Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda that takes…
Read More...

AstraZeneca’s Tagrisso (osimertinib)​ has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm)…
Read More...

Pfizer Inc. announced that it is voluntarily withdrawing all lots of OXBRYTA (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is…
Read More...

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced a new strategic…
Read More...

The Ministry of Health, Labour and Welfare Japan has approved Kisunla (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's Alzheimer's…
Read More...

Vanda Pharmaceuticals Inc. (Vanda) provided an update on its tradipitant development program. On September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve…
Read More...